Capital International Sarl Sells 17,656 Shares of Edwards Lifesciences Co. (NYSE:EW)

Capital International Sarl reduced its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 22.0% in the first quarter, according to its most recent filing with the SEC. The fund owned 62,461 shares of the medical research company’s stock after selling 17,656 shares during the period. Capital International Sarl’s holdings in Edwards Lifesciences were worth $5,969,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of EW. Vanguard Group Inc. raised its position in Edwards Lifesciences by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 52,964,394 shares of the medical research company’s stock valued at $5,061,277,000 after purchasing an additional 600,994 shares in the last quarter. Bank of New York Mellon Corp raised its position in Edwards Lifesciences by 9.5% during the 1st quarter. Bank of New York Mellon Corp now owns 18,973,304 shares of the medical research company’s stock valued at $1,813,089,000 after purchasing an additional 1,644,869 shares in the last quarter. Brown Advisory Inc. raised its position in Edwards Lifesciences by 20.1% during the 4th quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock valued at $1,386,333,000 after purchasing an additional 3,048,274 shares in the last quarter. Wellington Management Group LLP raised its position in Edwards Lifesciences by 2.4% during the 4th quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock valued at $1,283,098,000 after purchasing an additional 393,109 shares in the last quarter. Finally, Norges Bank bought a new stake in Edwards Lifesciences during the 4th quarter valued at $648,540,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Performance

Shares of EW stock traded up $2.67 on Friday, hitting $62.37. The company had a trading volume of 14,079,854 shares, compared to its average volume of 3,771,425. The firm has a market cap of $37.58 billion, a P/E ratio of 26.88, a price-to-earnings-growth ratio of 3.18 and a beta of 1.11. The company has a 50-day moving average price of $87.98 and a 200-day moving average price of $86.84. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. The business had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 24.55%. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.66 EPS. As a group, equities research analysts predict that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the topic of a number of analyst reports. Mizuho lifted their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, April 11th. Evercore ISI cut their price target on Edwards Lifesciences from $91.00 to $76.00 and set an “in-line” rating on the stock in a report on Thursday. Baird R W downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Thursday. Wells Fargo & Company cut their price target on Edwards Lifesciences from $99.00 to $90.00 and set an “overweight” rating on the stock in a report on Thursday. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $82.10.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total value of $466,450.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $4,378,659.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the completion of the transaction, the vice president now owns 173,849 shares of the company’s stock, valued at $14,639,824.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total value of $466,450.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $4,378,659.44. The disclosure for this sale can be found here. In the last 90 days, insiders sold 81,099 shares of company stock valued at $7,003,553. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.